.webp&w=384&q=75){kind=logo}
Loading, please wait...
Loading, please wait...
Star Health insurance growth is set for a significant surge as the company targets a Gross Written Premium (GWP) of Rs 24,000 crore for FY27. This objective represents a steady rise from the Rs 20,400 crore achieved in FY26. Consequently, the insurer aims to reach a landmark GWP of Rs 30,000 crore by FY28. Such ambitious milestones reflect the company's robust expansion strategy across the Indian market.
The company plans to launch two new affordable insurance products during the current fiscal year. Specifically, these plans will target residents in Tier 2 and Tier 3 cities to improve insurance penetration. Currently, Star Health offers 35 distinct plans that cater to diverse social segments. Furthermore, the retail health segment remains the primary business driver, contributing 96% of the total portfolio. Therefore, the company continues to prioritize individual and family coverage over group portfolios.
Improving the customer experience through faster claims processing is a central pillar of the firm's strategy. In FY26, Star Health successfully settled 30.6 lakh claims nationally, which totaled Rs 11,903 crore. Notably, the retail claims settlement ratio reached 92%, highlighting the insurer's reliability. Additionally, the company processes 92% of cashless claims within a three-hour window. This efficiency is bolstered by strong partnerships with a vast network of hospitals. As a result, patients can enjoy a smoother, more predictable healthcare journey.
The Andhra Pradesh and Telangana regions have emerged as significant growth hubs for the insurer. In FY26, the company settled claims worth Rs 1,254 crore in this region, marking a 24% year-on-year increase. Moreover, the regional GWP grew from Rs 1,928 crore in FY25 to Rs 2,268 crore in FY26. Management expects the business contribution from these states to rise from 10% to 15% within the next four years. Consequently, the company is strengthening its regional presence to support its national growth targets.
Q1: What is the projected GWP for Star Health in FY27?
Star Health aims to achieve a Gross Written Premium of Rs 24,000 crore in FY27, following a performance of Rs 20,400 crore in FY26.
Q2: How does the company plan to expand in smaller Indian cities?
The company will launch two new affordable insurance plans specifically designed for Tier 2 and Tier 3 cities to drive deeper market penetration.
Q3: What are the current claim settlement statistics for Star Health?
Star Health reports a 92% retail claims settlement ratio and processes 92% of cashless claims within a three-hour time frame.
Disclaimer: This content is for informational and educational purposes only. It does not constitute medical advice or replace professional judgment. Refer to the latest local and national guidelines for clinical practice.
References
Read summarized clinical updates, watch expert medical content, and earn CME certifications right from your smartphone.
Open your smartphone camera to scan and install.
Star Health targets Rs 24,000 crore GWP in FY27, focusing on Tier 2/3 cities and 92% retail claims settlement to drive growth in the Indian insurance market...
5 months ago
Novel diimide and hydrazone scaffolds, particularly compound #C4, synergistically reactivate latent HIV-1 when combined with JQ1 or PKC activators. Demonstrating donor-matched proviral transcription ex vivo and non-canonical signaling, these findings advance shock and kill strategies toward reservoir eradication.
Today
A cross-sectional study reveals that maternal RSV vaccination coverage reached only 43.7% in Argentina, with maternal vaccine knowledge being the sole independent predictor of uptake. Clinicians play a crucial role in eliminating informational and structural barriers to optimize infant health.
Today
Review how tailored exercise programs benefit frail older patients with heart failure. Explore pathophysiological mechanisms, individualized training prescriptions, and strategies to overcome adherence barriers in clinical practice.
Yesterday
This comparative study evaluates posterior labral tears with and without glenohumeral instability, highlighting distinct demographic patterns, MRI underestimation in stable shoulders, and successful arthroscopic repair outcomes.
Yesterday
A clinical study demonstrates that early intervention with tocilizumab, either as monotherapy or bridged with corticosteroids, achieves significant proptosis reduction and resolves active inflammation in treatment-naive thyroid eye disease.
Yesterday
